Free tool
FAERS Monitor: Lamzede
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761278 or its brand name (Lamzede, Velmanase Alfa-Tycv). Reports on generic versions are filed under their own applications.
Reports
56
Serious
31
55% of reports
Hospitalization
15
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue6
- product complaint5
- pyrexia5
- off label use4
- product administration interrupted4
- vomiting4
- abdominal pain3
- arthropathy3
- haemoglobin decreased3
- infusion related reaction3
- urticaria3
- blood creatinine increased2
- c-reactive protein increased2
- contusion2
- diarrhoea2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 6 |
| 2024 | 17 |
| 2025 | 25 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,103 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administration interruptedSignal | 4 | 191.5 | 74.5 | 579 |
| product complaintSignal | 5 | 74.1 | 32.1 | 292 |
| c-reactive protein increased | 2 | 20.6 | 5.3 | 20 |
| arthropathySignal | 3 | 20.3 | 6.7 | 37 |
| infusion related reactionSignal | 3 | 17.0 | 5.7 | 31 |
| blood creatinine increased | 2 | 11.5 | 3.0 | 10 |
| haemoglobin decreasedSignal | 3 | 11.0 | 3.6 | 18 |
| contusion | 2 | 7.8 | 2.0 | 6 |
| product dose omission issueSignal | 6 | 7.7 | 3.6 | 29 |
| urticariaSignal | 3 | 6.7 | 2.2 | 10 |
| pyrexiaSignal | 5 | 5.4 | 2.4 | 14 |
| abdominal painSignal | 3 | 4.8 | 1.6 | 6 |
| vomitingSignal | 4 | 3.2 | 1.2 | 4 |
| off label use | 4 | 1.7 | 0.7 | 1 |
| diarrhoea | 2 | 1.2 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.